
1. hybridoma (larchmt). 2008 oct;27(5):401-5. doi: 10.1089/hyb.2008.0030.

fusion b lymphoblastoid tumor cells expressing different antibiotic
resistance genes facilitates selection stable hybridomas.

lucas kg(1), bao l.

author information: 
(1)department pediatrics, penn state children's hospital, hershey,
pennsylvania 17033, usa. klucas@psu.edu

abstract development tumor vaccines generation tumor-specific
cytotoxic lymphocytes (ctl) limited fact many tumor cells
downregulate expression major histocompatibility complex (mhc) class and
ii molecules, well key co-stimulatory molecules cd80 cd86. an
immune response vaccine vitro stimulation tumor-specific ctl
requires antigen-presenting cells conveying tumor antigens context a
host's mhc antigens. used retroviral vector (murine stem cell virus)
encoding neomycin resistance transduce three pediatric tumor cell lines (two
neuroblastoma, one neuroepithelial tumor). ebv transformed b lymphoblastoid
cell line (blcl) transduced separate vector encoding puromycin
resistance green fluorescent protein, individual tumor lines fused 
the blcl, resulting hybridomas selected using antibiotics. 
resulting hybridoma cells expressed neural antigen gd2 well mhc class
i, class ii, cd 80, cd86. similar strategy could used produce stable 
hybridomas either vaccination ctl expansion.

doi: 10.1089/hyb.2008.0030 
pmid: 18781830  [indexed medline]

